Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Sep 13

PMID 27618313

Citations 13

Authors

Daichao Wu

Ming Guo

Michael A Philips

Lingzhi Qu

Longying Jiang

Jun Li

Xiaojuan Chen

Zhuchu Chen

Lin Chen

Yongheng Chen

Affiliations

Soon will be listed here.

Abstract

Aberrant FGFR4 signaling has been documented abundantly in various human cancers. The majority of FGFR inhibitors display significantly reduced potency toward FGFR4 compared to FGFR1-3. However, LY2874455 has similar inhibition potency for FGFR1-4 with IC50 less than 6.4 nM. To date, there is no published crystal structure of LY2874455 in complex with any kinase. To better understand the pan-FGFR selectivity of LY2874455, we have determined the crystal structure of the FGFR4 kinase domain bound to LY2874455 at a resolution of 2.35 Å. LY2874455, a type I inhibitor for FGFR4, binds to the ATP-binding pocket of FGFR4 in a DFG-in active conformation with three hydrogen bonds and a number of van der Waals contacts. After alignment of the kinase domain sequence of 4 FGFRs, and superposition of the ATP binding pocket of 4 FGFRs, our structural analyses reveal that the interactions of LY2874455 to FGFR4 are largely conserved in 4 FGFRs, explaining at least partly, the broad inhibitory activity of LY2874455 toward 4 FGFRs. Consequently, our studies reveal new insights into the pan-FGFR selectivity of LY2874455 and provide a structural basis for developing novel FGFR inhibitors that target FGFR1-4 broadly.

Citing Articles

Recent progress in emerging molecular targeted therapies for intrahepatic cholangiocarcinoma.

Kim Y, Song J, Kim N, Sim T RSC Med Chem. 2025; .

PMID: 39925737 PMC: 11800140. DOI: 10.1039/d4md00881b.

Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer.

Peng M, Deng J, Li X Mol Cancer. 2024; 23(1):256.

PMID: 39543657 PMC: 11566285. DOI: 10.1186/s12943-024-02167-9.

Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants.

Lin Q, Chen X, Qu L, Guo M, Wei H, Dai S Commun Chem. 2023; 5(1):100.

PMID: 36698015 PMC: 9814635. DOI: 10.1038/s42004-022-00718-z.

Alpinumisoflavone against cancer pro-angiogenic targets: In silico, In vitro, and In ovo evaluation.

Alos H, Billones J, Castillo A, Vasquez R Daru. 2022; 30(2):273-288.

PMID: 35925539 PMC: 9715906. DOI: 10.1007/s40199-022-00445-9.

Radiosensitization by the Selective Pan-FGFR Inhibitor LY2874455.

Darwis N, Horigome E, Li S, Adachi A, Oike T, Shibata A Cells. 2022; 11(11).

PMID: 35681425 PMC: 9179643. DOI: 10.3390/cells11111727.

References

Yamada S, Yamada S, Hayashi Y, Takahashi H, Teramoto A, Matsumoto K . Fibroblast growth factor receptor (FGFR) 4 correlated with the malignancy of human astrocytomas. Neurol Res. 2002; 24(3):244-8. DOI: 10.1179/016164102101199864. View

Gowardhan B, Douglas D, Mathers M, McKie A, McCracken S, Robson C . Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer. 2005; 92(2):320-7. PMC: 2361833. DOI: 10.1038/sj.bjc.6602274. View

Stephens P, Edkins S, Davies H, Greenman C, Cox C, Hunter C . A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet. 2005; 37(6):590-2. DOI: 10.1038/ng1571. View

Liu Y, Gray N . Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol. 2006; 2(7):358-64. DOI: 10.1038/nchembio799. View

Desnoyers L, Pai R, Ferrando R, Hotzel K, Le T, Ross J . Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene. 2007; 27(1):85-97. DOI: 10.1038/sj.onc.1210623. View

Taylor 6th J, Cheuk A, Tsang P, Chung J, Song Y, Desai K . Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest. 2009; 119(11):3395-407. PMC: 2769177. DOI: 10.1172/JCI39703. View

Knights V, Cook S . De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther. 2009; 125(1):105-17. DOI: 10.1016/j.pharmthera.2009.10.001. View

Roidl A, Foo P, Wong W, Mann C, Bechtold S, Berger H . The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells. Oncogene. 2009; 29(10):1543-52. DOI: 10.1038/onc.2009.432. View

Turner N, Grose R . Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010; 10(2):116-29. DOI: 10.1038/nrc2780. View

10.

Motoda N, Matsuda Y, Onda M, Ishiwata T, Uchida E, Naito Z . Overexpression of fibroblast growth factor receptor 4 in high-grade pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Int J Oncol. 2010; 38(1):133-43. View

11.

Wesche J, Haglund K, Haugsten E . Fibroblast growth factors and their receptors in cancer. Biochem J. 2011; 437(2):199-213. DOI: 10.1042/BJ20101603. View

12.

Zhao G, Li W, Chen D, Henry J, Li H, Chen Z . A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol Cancer Ther. 2011; 10(11):2200-10. DOI: 10.1158/1535-7163.MCT-11-0306. View

13.

Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C . Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem. 2011; 54(20):7066-83. DOI: 10.1021/jm2006222. View

14.

Gavine P, Mooney L, Kilgour E, Thomas A, Al-Kadhimi K, Beck S . AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012; 72(8):2045-56. DOI: 10.1158/0008-5472.CAN-11-3034. View

15.

Brooks A, Kilgour E, Smith P . Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res. 2012; 18(7):1855-62. DOI: 10.1158/1078-0432.CCR-11-0699. View

16.

Treiber D, Shah N . Ins and outs of kinase DFG motifs. Chem Biol. 2013; 20(6):745-6. DOI: 10.1016/j.chembiol.2013.06.001. View

17.

Ho H, Yeo A, Kang T, Tin Chua B . Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations. Drug Discov Today. 2013; 19(1):51-62. DOI: 10.1016/j.drudis.2013.07.021. View

18.

Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E . Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol. 2013; 25(3):552-563. PMC: 4433501. DOI: 10.1093/annonc/mdt419. View

19.

Nakanishi Y, Akiyama N, Tsukaguchi T, Fujii T, Sakata K, Sase H . The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer Ther. 2014; 13(11):2547-58. DOI: 10.1158/1535-7163.MCT-14-0248. View

20.

Duan Y, Chen L, Chen Y, Fan X . c-Src binds to the cancer drug Ruxolitinib with an active conformation. PLoS One. 2014; 9(9):e106225. PMC: 4157781. DOI: 10.1371/journal.pone.0106225. View